SecBot SecBot
SECBOTREPLAY Home › Report › ARVN

ARVN · Arvinas announced that Phase 1 clinical trial data for its…

Arvinas Inc. · PRESS-RELEASE filed Mar 11, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 11, 2026 at 07:00 ET

Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug ARV-102 will be presented at the AD/PD™ 2026 conference. The data will include safety, pharmacokinetic, and pharmacodynamic results from multiple doses in Parkinson’s patients, with a planned Phase 1b trial in progressive supranuclear palsy (PSP) pending regulatory feedback.

  • ARV-102 is an oral PROTAC degrader targeting LRRK2, designed to cross the blood-brain barrier.
  • Phase 1 data on safety, PK, and PD will be presented at AD/PD™ 2026 on March 18, 2026.
  • Arvinas plans to initiate a Phase 1b trial in PSP patients in the first half of 2026, pending regulatory feedback.
  • No efficacy data or clinical outcomes were disclosed, only safety and pharmacological profiles.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access